Literature DB >> 1590828

Non-enzymatic glycation of apolipoprotein B in the sera of diabetic and non-diabetic subjects.

F J Tames1, M I Mackness, S Arrol, I Laing, P N Durrington.   

Abstract

Utilising a combination of m-aminophenyl-borate affinity chromatography and an immunoradiometric assay for apolipoprotein B (apo B), we have developed a specific and highly sensitive (6 ng/ml) procedure for the assay of glycated apo B. We studied 52 diabetic patients, 50 non-diabetic control subjects and 12 patients heterozygous for familial hypercholesterolaemia (FH). Both insulin-dependent and non-insulin dependent diabetics were included in our study. Total apo B in the diabetics (108 +/- 5 mg/dl; mean +/- S.E.M) was increased (controls: 95 +/- 4 mg/dl; P less than 0.05). In the FH group the serum apo B concentration (216 +/- 24 mg/dl) was significantly higher (P less than 0.001) than both the other groups studied. Both the serum glycated apo B concentration (9.3 +/- 0.8 mg/dl versus 4.8 +/- 0.7 mg/dl) and the percentage glycated apo B (7.9 +/- 0.4% compared to 3.9 +/- 0.2%) were significantly higher in the diabetics than in non-diabetic controls (P less than 0.001). A positive correlation was found between the percentage of glycated apo B and glycated haemoglobin (r = 0.65; P less than 0.001) and fasting glucose concentration (r = 0.52; P less than 0.001) in diabetics. The percentage of glycated apo B in FH patients was not significantly different from controls, but the serum concentration of glycated apo B, because of the greatly increased total level of apo B was raised (8.2 +/- 1.4 mg/dl) to a similar extent to that of the diabetics.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1590828     DOI: 10.1016/0021-9150(92)90260-n

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  20 in total

1.  Familial hypercholesterolaemia.

Authors:  A David Marais
Journal:  Clin Biochem Rev       Date:  2004-02

Review 2.  Presence and Risk Factors for Glaucoma in Patients with Diabetes.

Authors:  Brian J Song; Lloyd Paul Aiello; Louis R Pasquale
Journal:  Curr Diab Rep       Date:  2016-12       Impact factor: 4.810

Review 3.  Oxidative stress in the placenta.

Authors:  Leslie Myatt; Xiaolan Cui
Journal:  Histochem Cell Biol       Date:  2004-07-10       Impact factor: 4.304

4.  Glycated LDL increases monocyte CC chemokine receptor 2 expression and monocyte chemoattractant protein-1-mediated chemotaxis.

Authors:  Kikuo Isoda; Eduardo Folco; M Reza Marwali; Fumitaka Ohsuzu; Peter Libby
Journal:  Atherosclerosis       Date:  2007-12-27       Impact factor: 5.162

5.  Inhibiting low-density lipoprotein glycation ameliorates increased cholesteryl ester synthesis in macrophages and hypercholesterolemia and aortic lipid peroxidation in streptozotocin diabetic rats.

Authors:  Margo P Cohen; Elizabeth A Shea; Van-Yu Wu
Journal:  Metabolism       Date:  2009-11-18       Impact factor: 8.694

6.  Glycated LDL increase VCAM-1 expression and secretion in endothelial cells and promote monocyte adhesion through mechanisms involving endoplasmic reticulum stress.

Authors:  Laura Toma; Gabriela M Sanda; Mariana Deleanu; Camelia S Stancu; Anca V Sima
Journal:  Mol Cell Biochem       Date:  2016-05-20       Impact factor: 3.396

Review 7.  Phytotherapy in diabetes: Review on potential mechanistic perspectives.

Authors:  Hanan S El-Abhar; Mona F Schaalan
Journal:  World J Diabetes       Date:  2014-04-15

Review 8.  Amadori-modified glycated serum proteins and accelerated atherosclerosis in diabetes: pathogenic and therapeutic implications.

Authors:  Margo P Cohen; Fuad N Ziyadeh; Sheldon Chen
Journal:  J Lab Clin Med       Date:  2006-05

9.  Glycation of paraoxonase-1 inhibits its activity and impairs the ability of high-density lipoprotein to metabolize membrane lipid hydroperoxides.

Authors:  M Mastorikou; B Mackness; Y Liu; M Mackness
Journal:  Diabet Med       Date:  2008-09       Impact factor: 4.359

10.  Autoantibodies Against Methylglyoxal-Modified Apolipoprotein B100 and ApoB100 Peptide Are Associated With Less Coronary Artery Atherosclerosis and Retinopathy in Long-Term Type 1 Diabetes.

Authors:  Kari Anne Sveen; Kristine Bech Holte; Mona Svanteson; Kristian F Hanssen; Jan Nilsson; Eva Bengtsson; Tore Julsrud Berg
Journal:  Diabetes Care       Date:  2021-04-15       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.